Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

medochemie ltd. - metforminhydrochlorid, vildagliptin - filmovertrukne tabletter - 50+850 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

tiefenbacher gmbh - metforminhydrochlorid, vildagliptin - filmovertrukne tabletter - 50+1000 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

novo nordisk a/s - insulin aspart - diabetes mellitus - drugs used in diabetes, insulins and analogues for injection, fast-acting - behandling af diabetes mellitus hos voksne, unge og børn i alderen 1 år og derover.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformin-hydrochlorid - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformin-hydrochlorid - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 for tilgængelige data på forskellige kombinationer).

Den Europæiske Union - dansk - EMA (European Medicines Agency)

sanofi winthrop industrie - lixisenatid - diabetes mellitus, type 2 - drugs used in diabetes, glucagon-like peptide-1 (glp-1) analogues - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

novartis europharm limited  - vildagliptin, metformin-hydrochlorid - diabetes mellitus, type 2 - narkotika anvendt i diabetes - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, type 2 - narkotika anvendt i diabetes - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 for tilgængelige data på forskellige kombinationer).

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sun pharmaceutical industries europe bv - octreotidacetat - injektionsvæske, opløsning - 0,1 mg/1 ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sun pharmaceutical industries europe bv - octreotidacetat - injektionsvæske, opløsning - 1 mg/5 ml